From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
Top Cited Papers
Open Access
- 28 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 37 (1), 4-15
- https://doi.org/10.1038/npp.2011.181
Abstract
Glutamate is the primary excitatory neurotransmitter in mammalian brain. Disturbances in glutamate-mediated neurotransmission have been increasingly documented in a range of neuropsychiatric disorders including schizophrenia, substance abuse, mood disorders, Alzheimer's disease, and autism-spectrum disorders. Glutamatergic theories of schizophrenia are based on the ability of N-methyl-D-aspartate receptor (NMDAR) antagonists to induce schizophrenia-like symptoms, as well as emergent literature documenting disturbances of NMDAR-related gene expression and metabolic pathways in schizophrenia. Research over the past two decades has highlighted promising new targets for drug development based on potential pre- and postsynaptic, and glial mechanisms leading to NMDAR dysfunction. Reduced NMDAR activity on inhibitory neurons leads to disinhibition of glutamate neurons increasing synaptic activity of glutamate, especially in the prefrontal cortex. Based on this mechanism, normalizing excess glutamate levels by metabotropic glutamate group 2/3 receptor agonists has led to potential identification of the first non-monoaminergic target with comparable efficacy as conventional antipsychotic drugs for treating positive and negative symptoms of schizophrenia. In addition, NMDAR has intrinsic modulatory sites that are active targets for drug development, several of which show promise in preclinical/early clinical trials targeting both symptoms and cognition. To date, most studies have been done with orthosteric agonists and/or antagonists at specific sites. However, allosteric modulators, both positive and negative, may offer superior efficacy with less danger of downregulation.Keywords
This publication has 113 references indexed in Scilit:
- NR3A-containing NMDARs promote neurotransmitter release and spike timing–dependent plasticityNature Neuroscience, 2011
- Cognitive Control Deficits in Schizophrenia: Mechanisms and MeaningNeuropsychopharmacology, 2010
- Glutaminase-Deficient Mice Display Hippocampal Hypoactivity, Insensitivity to Pro-Psychotic Drugs and Potentiated Latent Inhibition: Relevance to SchizophreniaNeuropsychopharmacology, 2009
- Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in SchizophreniaNeuropsychopharmacology, 2009
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaTrends in Pharmacological Sciences, 2008
- Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosisPsychopharmacology, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal CortexBiological Psychiatry, 2007
- A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in SchizophreniaNeuropsychopharmacology, 2007
- Fine-Tuning of Awake Prefrontal Cortex Neurons by Clozapine: Comparison With Haloperidol and N-DesmethylclozapineBiological Psychiatry, 2007